REGEN BIOPHARMA, INC.: 10-Q/A filed 2017-04-28

Name: REGEN BIOPHARMA, INC.: 10-Q/A filed 2017-04-28
Creator: REGEN BIOPHARMA, INC.

What REGEN BIOPHARMA, INC. reported in its quarterly report amendment filed 2017-04-28 (fiscal Q1 2016): 13 published measures, 13 facts as tagged in accession 0001607062-17-000165.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form: 10-Q/A (quarterly report amendment)
Filed: 2017-04-28
Fiscal period: fiscal Q1 2016
Accession: 0001607062-17-000165 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGEN BIOPHARMA, INC. filings.

Reported measures

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2014-12-31	53,622	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	-219,191	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	-197,103	USD	92

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	0	USD	92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	250,725	USD	92

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	52,000,576	shares	92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	-213,409	USD	92

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	6,042	USD	92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	2,237	USD	92

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2015-12-31	0	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	-219,191	USD	92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	139,453	USD	92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	196	USD	92

Inspect the source

Entity: REGEN BIOPHARMA, INC. / CIK 0001589150
Captured: 2026-09-20T09:23:48.532Z
SEC response SHA-256: 0bbe246b6080c7701ba978807745a4ba9de62971ab4db32e8d3e2fa2c4f26a87

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001589150.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))